본문 바로가기
KERD
논문KCI 등재

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults

김진은|Theodore F. Tsai
대한감염학회 (The Korean Society Of Infectious Diseases)|2013.06|Infection and Chemotherapy|제45권 제2호|pp. 159-174

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

InfluenzaAdjuvantInfluenza vaccineMF59Emulsion adjuvant
주제분류내과학

초록

Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere. Conventional inactivated influenza vaccine (IIV) is less immunogenic and efficacious (-50%) in older than in young adults, but adjuvanting the vaccine with oil-in-water emulsion MF59® increases immunogenicity, resulting in comparatively higher levels of hemagglutination inhibition antibodies and greater protection against all influenza, as well as cases requiring hospitalization. A recent observational study demonstrated that the adjuvanted vaccine protected older adults against influenza in a year when nonadjuvanted IIV was ineffective. In another multiyear study, the adjuvanted vaccine was estimated to be 25% more effective in preventing pneumonia and influenza hospitalizations compared to nonadjuvanted vaccine. Although MF59-adjuvanted vaccine is transiently more reactogenic than nonadjuvanted vaccine, there is no evidence that it increases risks for serious adverse events, including those with an autoimmune etiology. Experience thus far indicates a favorable balance of benefit to risk for MF59. This may reflect the adjuvant’s mechanism of action in which the squalene oil emulsion increases antibody responses to co-administered antigen without acting more generally as an immunopotentiator.

Abstract

Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere. Conventional inactivated influenza vaccine (IIV) is less immunogenic and efficacious (-50%) in older than in young adults, but adjuvanting the vaccine with oil-in-water emulsion MF59® increases immunogenicity, resulting in comparatively higher levels of hemagglutination inhibition antibodies and greater protection against all influenza, as well as cases requiring hospitalization. A recent observational study demonstrated that the adjuvanted vaccine protected older adults against influenza in a year when nonadjuvanted IIV was ineffective. In another multiyear study, the adjuvanted vaccine was estimated to be 25% more effective in preventing pneumonia and influenza hospitalizations compared to nonadjuvanted vaccine. Although MF59-adjuvanted vaccine is transiently more reactogenic than nonadjuvanted vaccine, there is no evidence that it increases risks for serious adverse events, including those with an autoimmune etiology. Experience thus far indicates a favorable balance of benefit to risk for MF59. This may reflect the adjuvant’s mechanism of action in which the squalene oil emulsion increases antibody responses to co-administered antigen without acting more generally as an immunopotentiator.

참고문헌 (72)

  1. Lozano R, "Global and regional mortality from 235 causes ofdeath for 20 age groups in 1990 and 2010: a systematicanalysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2095~2128 (2012)
  2. Monto AS, "Influenzacontrol in the 21st century: Optimizing protectionof older adults", Vaccine, 27, pp.5043~5053 (2009)
  3. "Statistical Handbook of Japan 2012" (2012)[URL]
  4. Cai L, "Cost-effectivenessanalysis of influenza and pneumococcal vaccinationsamong elderly people in Japan", Kobe J Med Sci, 52, pp.97~109 (2006)
  5. Osterholm MT, "Efficacyand effectiveness of influenza vaccines: a systematicreview and meta-analysis", Lancet Infect Dis, 12, pp.36~44 (2012)
  6. Simonsen L, "Mortality benefits of influenza vaccination in elderly people:an ongoing controversy", Lancet Infect Dis, 7, pp.658~666 (2007)
  7. Thijs C, "Mortality benefits of influenza vaccination in elderly people", Lancet Infect Dis, 8, pp.460~461 (2008)
  8. Goodwin K, "Antibody response toinfluenza vaccination in the elderly: a quantitative review", Vaccine, 24, pp.1159~1169 (2006)
  9. Song JY, "Long-term immunogenicityof influenza vaccine among the elderly: Risk factors forpoor immune response and persistence", Vaccine, 28, pp.3929~3935 (2010)
  10. Reber AJ, "Immunosenescence and challenges of vaccinationagainst influenza in the aging population", AgingDis, 3, pp.68~90 (2012)
  11. Orsi A, "Cross-protectionagainst drifted influenza viruses: Options offered byadjuvanted and intradermal vaccines", Hum Vaccin Immunother, 9 (2013)
  12. Podda A, "The adjuvanted influenza vaccines with noveladjuvants: experience with the MF59-adjuvanted vaccine", Vaccine, 19, pp.2673~2678 (2001)
  13. O'Hagan DT, "The history of MF59(® ) adjuvant: a phoenix that arosefrom the ashes", Expert Rev Vaccines, 12, pp.13~30 (2013)
  14. "Physicians' Update - 1 October2012" (2012)[URL]
  15. Ansaldi F, "Cross-protectionby MF59-adjuvanted influenza vaccine: neutralizing andhaemagglutination-inhibiting antibody activity againstA(H3N2) drifted influenza viruses", Vaccine, 26, pp.1525~1529 (2008)
  16. Squarcione S, "Comparisonof the reactogenicity and immunogenicity of a split and asubunit-adjuvanted influenza vaccine in elderly subjects", Vaccine, 21, pp.1268~1274 (2003)
  17. Ohmit SE, "Influenza vaccine effectivenessin the community and the household", Clin Infect Dis, 56, pp.1363~1369 (2013)
  18. Song JY, "Long-term immunogenicity ofthe pandemic influenza A", H1N1 2009 vaccine amonghealth care workers: influence of prior seasonal influenzavaccination, 2013, pp.20, 513~516
  19. Medina RA, "Influenza A viruses: new researchdevelopments", Nat Rev Microbiol, 9, pp.590~603 (2011)
  20. Russell CA, "The global circulation of seasonalinfluenza A (H3N2) viruses", Science, 320, pp.340~346 (2008)
  21. Khurana S, "MF59adjuvant enhances diversity and affinity of antibody-mediatedimmune response to pandemic influenza vaccines", Sci Transl Med, 3, pp.85~48 (2011)
  22. Kang S, "Epidemiologic study of human influenza virus infection inSouth Korea from 1999 to 2007: origin and evolution of A", Fuj ian, 2002- l ike s t rains, pp.J Cl in Microbiol, 2010[DOI]
  23. Cheng X, "Epidemiological dynamicsand phylogeography of influenza virus in southernChina", J Infect Dis, 207, pp.106~114 (2013)
  24. "2012-2013 Influenza season week 13 ending March 30,2013" (2013)[URL]
  25. Zhou H, "Hospitalizations associated with influenza and respiratorysyncytial virus in the United States, 1993-2008", ClinInfect Dis, 54, pp.1427~1436 (2012)
  26. Madjid M, "Influenzaand atherosclerosis: vaccination for cardiovascular diseaseprevention", Expert Opin Biol Ther, 5, pp.91~96 (2005)
  27. Barker WH, "A study of the impact of influenzaon the functional status of frail older people", ArchIntern Med, 158, pp.645~650 (1998)
  28. Boyd CM, "Recovery ofactivities of daily living in older adults after hospitalizationfor acute medical illness", J Am Geriatr Soc, 56, pp.2171~2179 (2008)
  29. Covinsky KE, "Loss ofindependence in activities of daily living in older adultshospitalized with medical illnesses: increased vulnerabilitywith age", J Am Geriatr Soc, 51, pp.451~458 (2003)
  30. Seo YB, "Effectiveness of the influenzavaccine at preventing hospitalization due to acutelower respiratory infection and exacerbation of chroniccardiopulmonary disease in Korea during 2010-2011", Vaccine, 31, pp.1426~1430 (2013)
  31. Talbot HK, "Effectiveness of influenza vaccine for preventinglaboratory-confirmed influenza hospitalizations inadults, 2011-2012 influenza season", Clin Infect Dis, 56, pp.1774~1777 (2013)
  32. Puig-Barbera J, "Effectiveness of the MF59-adjuvantedinfluenza vaccine in preventing emergency admissionsfor pneumonia in the elderly over 64 years ofage", Vaccine, 23, pp.283~289 (2004)
  33. Puig-Barbera J, "Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisationsfor cardiovascular disease, cerebrovasculardisease and pneumonia in the elder ly", Vaccine, 25, pp.7313~7321 (2007)
  34. Gasparini R, "Effectivenessof adjuvanted seasonal influenza vaccines (InflexalV ® and Fluad ®) in preventing hospitalization for influenzaand pneumonia in the elderly: a matched casecontrolstudy", Hum Vaccin Immunother, 9, pp.144~152 (2013)
  35. Puig-Barbera J, "Effectiveness of the 2010-2011 seasonal influenza vaccinein preventing confirmed influenza hospitalizations inadults: a case-case comparison, case-control study", Vaccine, 30, pp.5714~5720 (2012)
  36. Eick-Cost AA, "Effectiveness of seasonal influenza vaccines against influenza-associated illnesses among US military personnelin 2010-11: a case-cont rol approach", PLoS One, 7, pp.e41435~ (2012)
  37. Kissling E, "I-MOVE multi-centrecase control study 2010-11: overall and stratified estimatesof influenza vaccine effectiveness in Europe", PLoS One, 6, pp.e27622~ (2011)
  38. Pebody RG, "Age-specific vaccine effectiveness of seasonal2010", 2011 and pandemic influenza A(H1N1) 2009vaccines in preventing influenza in the United Kingdom, 2012, 1~11
  39. Skowronski DM, "A sentinel platform to evaluate influenza vaccineeffectiveness and new variant circulation, Canada2010-2011 season", Clin Infect Dis, 55, pp.332~342 (2012)
  40. Treanor JJ, "US Flu-VE Network. Effectiveness of seasonalinfluenza vaccines in the United States during a seasonwith circulation of all three vaccine strains", Clin InfectDis, 55, pp.951~959 (2012)
  41. Iob A, "Evidence of increasedclinical protection of an MF59-adjuvant influenzavaccine compared to a non-adjuvant vaccine among elderlyresidents of long-term care facilities in Italy", EpidemiolInfect, 133, pp.687~693 (2005)
  42. Mannino S, "Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy", Am J Epidemiol, 176, pp.527~533 (2012)
  43. Levandowski RA, "Antibody responses to influenzaB viruses in immunologically unprimed children", Pediatrics, 88, pp.1031~1036 (1991)
  44. Reed C, "Public health impactof including two lineages of influenza B in a quadrivalentseasonal influenza vaccine", Vaccine, 30, pp.1993~1998 (2012)
  45. Dreyfus C, "Highly conserved protective epitopes on influenzaB viruses", Science, 337, pp.1343~1348 (2012)
  46. Janjua NZ, "Estimates of influenza vaccine effectiveness for2007-2008 from Canada's sentinel surveillance system:cross-protection against major and minor variants", J InfectDis, 205, pp.1858~1868 (2012)
  47. Konrad S, "Influenza Comparative Vaccine Effectiveness Study", Annual meeting of 10th Canadian Immunization Conference, 4 (2012)
  48. Castilla J, "Primary HealthCare Sentinel Network; Network for Influenza Surveillancein Hospitals of Navarre. Decline in influenza vaccineeffectiveness with time after vaccination, season 2011", 12, 2013, pp.18, ~
  49. Kissling E, "Low and decreasingvaccine effectiveness against influenza A(H3) in 2011", 12among vaccination target groups in Europe: results fromthe I-MOVE multicentre case-control study, 2013, pp.18, ~
  50. MacIntosh VH, "Mid-season influenzavaccine effectiveness 2011-2012: a Department of DefenseGlobal, Laboratory-based, Influenza Surveillance Systemcase-control study estimate", Vaccine, 31, pp.1651~1655 (2013)
  51. Pebody R, "Vaccine effectivenessof 2011", 12 trivalent seasonal influenza vaccine inpreventing laboratory-confirmed influenza in primarycare in the United Kingdom: evidence of waning intraseasonalprotection, 2013, pp.18, ~
  52. Schultze V, "Safety of MF59 adjuvant", Vaccine, 26, pp.3209~3222 (2008)
  53. Pellegrini M, "MF59-adjuvanted versus non-adjuvanted influenzavaccines: integrated analysis from a large safety database", Vaccine, 27, pp.6959~6965 (2009)
  54. Cheong HJ, "Immunogenicity and safety of the influenzaA", H1N1 2009 inactivated split-virus vaccine inyoung and older adults: MF59-adjuvanted vaccine versusnonadjuvanted vaccine, 2011, pp.18, 1358~1364
  55. Dell'Era L, "Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children withjuvenile idiopathic arthritis", Vaccine, 30, pp.936~940 (2012)
  56. Moro ML, "SaFoH1N1 working group. A population based cohortstudy to assess the safety of pandemic influenza vaccineFocetria in Emilia-Romagna region, Italy - part two", Vaccine, 31, pp.1438~1446 (2013)
  57. Candela S, "SaFoH1N1working group. An early (3-6 weeks) active surveillancestudy to assess the safety of pandemic influenza vaccineFocetria® in a province of Emilia-Romagna region, Italy -part one", Vaccine, 31, pp.1431~1437 (2013)
  58. Isai A, "Autoimmunedisorders after immunisation with InfluenzaA", H1N1 vaccines with and without adjuvant: EudraVigilancedata and literature review, 2012, pp.30, 7123~7129
  59. Banzhoff A, "Passive surveillance of adverseevents of an MF59-adjuvanted H1N1v vaccine duringthe pandemic mass vaccinations", Hum Vaccin, 7, pp.539~548 (2011)
  60. Moro ML, "SaFoH1N1 working group. A population based cohortstudy to assess the safety of pandemic influenza vaccineFocetria in Emilia-Romagna region, Italy - part two", Vaccine, 31, pp.1438~1446 (2013)
  61. Biscayart C, "Argentina´s integral prevention of influenza:a successful experience of an emerging country", Annualmeeting of Influenza vaccines for the world, pp.10~ (2012)
  62. Nohynek H, "AS03 adjuvanted AH1N1vaccine associated with an abrupt increase in the incidenceof childhood narcolepsy in Finland", PLoS One, 7, pp.e33536~ (2012)
  63. Miller E, "Risk of narcolepsy in children andyoung people receiving AS03 adjuvanted pandemic A", H1N1 2009 influenza vaccine: retrospective analysis, 2013, pp.346, f794~
  64. Tsai TF, "Explorations of clinical trials andpharmacovigilance databases of MF59®-adjuvanted influenzavaccines for associated cases of narcolepsy", Scand JInfect Dis, 43, pp.702~706 (2011)
  65. Tsai TF, "Isthe adjuvant solely to blame", BMJ, 346, pp.f2375~ (2013)
  66. Choe YJ, "No association between influenzaA(H1N1)pdm09 vaccination and narcolepsy in SouthKorea: an ecological study", Vaccine, 30, pp.7439~7442 (2012)
  67. Han F, "Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic", Ann Neurol (2012)
  68. Han F, "Narcolepsy onset is seasonal and increased followingthe 2009 H1N1 pandemic in China", Ann Neurol, 70, pp.410~417 (2011)
  69. O'Hagan DT, "The mechanismof action of MF59 - an innately attractive adjuvantformulation", Vaccine, 30, pp.4341~4348 (2012)
  70. Calabro S, "Vaccineadjuvants alum and MF59 induce rapid recruitment of neutrophilsand monocytes that participate in antigen transportto draining lymph nodes", Vaccine, 29, pp.1812~1823 (2011)
  71. Mosca F, "Molecular andcellular signatures of human vaccine adjuvants", Proc NatlAcad Sci U S A, 105, pp.10501~10506 (2008)
  72. Seubert A, "Adjuvanticity of the oil-in-water emulsionMF59 is independent of Nlrp3 inflammasome but requiresthe adaptor protein MyD88", Proc Natl Acad Sci U SA, 108, pp.11169~11174 (2011)

관련 논문AI추천

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years김창오, 유병욱, Allen Izu, Ashwani Kumar Arora, Esther Heijnen대한감염학회 · Infection and Chemotherapy2018 · 제50권 제4호Influenza Vaccines: Unmet Needs and Recent Developments김우주, 노지윤대한감염학회 · Infection and Chemotherapy2013 · 제45권 제4호Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea한스 복, 김현균, 마상혁, 허재원, 바바슈리 구나팔라이아대한소아감염학회 · Pediatric Infection and Vaccine2011 · 제18권 제1호The Korean Influenza National Immunization Program: History and Present Status김윤주, 노지윤, 송준영, 윤재원, 전채민, 정희진대한감염학회 · Infection and Chemotherapy2017 · 제49권 제4호Recommendations for Influenza Vaccination in Immunocompromised PatientsChoi Jun Yong, Choi Min Joo, Choi Won Suk, Choo Eun Ju, Heo Jung Yeon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Park Wan Beom, Song Joon Young대한감염학회 · Infection and Chemotherapy2025 · 제57권 제2호How to Improve Influenza Vaccination Rates in the U.S.Byung-Kwang Yoo대한예방의학회 · 예방의학회지2011 · 제44권 제4호

이 간행물의 다른 논문 (15건)

Genomic Basis for Methicillin Resistance in Staphylococcus aureusTomomi Hishinuma, Miki Matsuo, Kyoko Kuwahara-Arai, Tadashi Baba, Keiichi Hiramatsu, Teruyo Ito, Sae Tsubakishita, Takashi Sasaki, Fumihiko Takeuchi, Yuh Morimoto, Yuki Katayamapp. 117-136Leptospirosis in the Republic of Korea: Historical Perspectives, Current Status and Future Challenges김민자pp. 137-144The Changing Epidemiology of Childhood Pneumococcal Disease in Korea최영준, 이환종, 최은화pp. 145-148Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea강정옥, 배현주, 서미란, 김지은, 최태열pp. 175-183The Long and Short Incubation Periods of Plasmodium vivax Malaria in Korea: The Characteristics and Relating Factors연성기, 장재연, 김시헌, 곽진, 조수남, 김선자pp. 184-193
원문 보기